Cargando…

Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy

Cyclic dinucleotides (CDNs) as stimulator of interferon genes (STING) agonists capable of inducing strong antitumor innate immune response are highly promising for tumor immunotherapy. The efficacy of these CDNs is, however, reduced greatly by their fast clearance, poor cell uptake and inefficient c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Huan, Guo, Beibei, Qiu, Xinyun, Xia, Yifeng, Qu, Yan, Cheng, Liang, Meng, Fenghua, Zhong, Zhiyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958419/
https://www.ncbi.nlm.nih.gov/pubmed/35386324
http://dx.doi.org/10.1016/j.bioactmat.2022.02.029
_version_ 1784676938691903488
author Zheng, Huan
Guo, Beibei
Qiu, Xinyun
Xia, Yifeng
Qu, Yan
Cheng, Liang
Meng, Fenghua
Zhong, Zhiyuan
author_facet Zheng, Huan
Guo, Beibei
Qiu, Xinyun
Xia, Yifeng
Qu, Yan
Cheng, Liang
Meng, Fenghua
Zhong, Zhiyuan
author_sort Zheng, Huan
collection PubMed
description Cyclic dinucleotides (CDNs) as stimulator of interferon genes (STING) agonists capable of inducing strong antitumor innate immune response are highly promising for tumor immunotherapy. The efficacy of these CDNs is, however, reduced greatly by their fast clearance, poor cell uptake and inefficient cytosolic transportation. Here, we report that reduction-responsive biodegradable chimaeric polymersomes (CPs) markedly enhance tumor retention and cytosolic delivery of a synthetic CDN, ADU-S100, and bolster STING pathway activation in the tumor microenvironment and tumor draining lymph nodes, giving significantly better tumor repression and survival of B16F10 melanoma-bearing mice compared with free CDN control. The superiority of CPs-mediated CDN delivery is further verified in combination therapy with low-dose fractionated radiation, which brings about clearly stronger and longer-term immunotherapeutic effects and protection against tumor re-challenge. The development of nano-STING agonists that are able to overcome the delivery barriers of CDNs represents an effective strategy to potentiate cancer immunotherapy.
format Online
Article
Text
id pubmed-8958419
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher KeAi Publishing
record_format MEDLINE/PubMed
spelling pubmed-89584192022-04-05 Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy Zheng, Huan Guo, Beibei Qiu, Xinyun Xia, Yifeng Qu, Yan Cheng, Liang Meng, Fenghua Zhong, Zhiyuan Bioact Mater Article Cyclic dinucleotides (CDNs) as stimulator of interferon genes (STING) agonists capable of inducing strong antitumor innate immune response are highly promising for tumor immunotherapy. The efficacy of these CDNs is, however, reduced greatly by their fast clearance, poor cell uptake and inefficient cytosolic transportation. Here, we report that reduction-responsive biodegradable chimaeric polymersomes (CPs) markedly enhance tumor retention and cytosolic delivery of a synthetic CDN, ADU-S100, and bolster STING pathway activation in the tumor microenvironment and tumor draining lymph nodes, giving significantly better tumor repression and survival of B16F10 melanoma-bearing mice compared with free CDN control. The superiority of CPs-mediated CDN delivery is further verified in combination therapy with low-dose fractionated radiation, which brings about clearly stronger and longer-term immunotherapeutic effects and protection against tumor re-challenge. The development of nano-STING agonists that are able to overcome the delivery barriers of CDNs represents an effective strategy to potentiate cancer immunotherapy. KeAi Publishing 2022-03-04 /pmc/articles/PMC8958419/ /pubmed/35386324 http://dx.doi.org/10.1016/j.bioactmat.2022.02.029 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Zheng, Huan
Guo, Beibei
Qiu, Xinyun
Xia, Yifeng
Qu, Yan
Cheng, Liang
Meng, Fenghua
Zhong, Zhiyuan
Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
title Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
title_full Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
title_fullStr Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
title_full_unstemmed Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
title_short Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
title_sort polymersome-mediated cytosolic delivery of cyclic dinucleotide sting agonist enhances tumor immunotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958419/
https://www.ncbi.nlm.nih.gov/pubmed/35386324
http://dx.doi.org/10.1016/j.bioactmat.2022.02.029
work_keys_str_mv AT zhenghuan polymersomemediatedcytosolicdeliveryofcyclicdinucleotidestingagonistenhancestumorimmunotherapy
AT guobeibei polymersomemediatedcytosolicdeliveryofcyclicdinucleotidestingagonistenhancestumorimmunotherapy
AT qiuxinyun polymersomemediatedcytosolicdeliveryofcyclicdinucleotidestingagonistenhancestumorimmunotherapy
AT xiayifeng polymersomemediatedcytosolicdeliveryofcyclicdinucleotidestingagonistenhancestumorimmunotherapy
AT quyan polymersomemediatedcytosolicdeliveryofcyclicdinucleotidestingagonistenhancestumorimmunotherapy
AT chengliang polymersomemediatedcytosolicdeliveryofcyclicdinucleotidestingagonistenhancestumorimmunotherapy
AT mengfenghua polymersomemediatedcytosolicdeliveryofcyclicdinucleotidestingagonistenhancestumorimmunotherapy
AT zhongzhiyuan polymersomemediatedcytosolicdeliveryofcyclicdinucleotidestingagonistenhancestumorimmunotherapy